{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:55:44Z","timestamp":1790063744308,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00228-022-03291-5","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T10:03:02Z","timestamp":1645005782000},"page":"823-829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance"],"prefix":"10.1007","volume":"78","author":[{"given":"Sareh","family":"Razzazzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilad Alavi","family":"Darazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreaza","family":"Hajiesmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Salamzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mahboubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Sadeghnezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-4444","authenticated-orcid":false,"given":"Zahra","family":"Sahraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"3291_CR1","doi-asserted-by":"crossref","unstructured":"Mahmoud S, Shen C (2017) Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics 9(3):E36","DOI":"10.3390\/pharmaceutics9030036"},{"key":"3291_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","volume":"24","author":"FB Sime","year":"2015","unstructured":"Sime FB, Udy AA, Roberts JA (2015) Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol 24:1\u20136","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"3291_CR3","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","volume":"39","author":"AA Udy","year":"2013","unstructured":"Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39(12):2070\u20132082","journal-title":"Intensive Care Med"},{"key":"3291_CR4","doi-asserted-by":"crossref","unstructured":"Hobbs AL et al (2015) Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. Pharmacotherapy 35(11):1063\u20131075","DOI":"10.1002\/phar.1653"},{"issue":"3","key":"3291_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2017.11.013","volume":"51","author":"C Carrie","year":"2018","unstructured":"Carrie C et al (2018) Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of \u03b2-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents 51(3):443\u2013449","journal-title":"Int J Antimicrob Agents"},{"key":"3291_CR6","unstructured":"Aa U et al (2011) Sub-therapeutic initial-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 10"},{"issue":"6","key":"3291_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QCO.0000000000000494","volume":"31","author":"AJ Heffernan","year":"2018","unstructured":"Heffernan AJ et al (2018) How to optimize antibiotic pharmacokinetic\/pharmacodynamics for Gram-negative infections in critically ill patients. Curr Opin Infect Dis 31(6):555\u2013565","journal-title":"Curr Opin Infect Dis"},{"key":"3291_CR8","doi-asserted-by":"crossref","unstructured":"Mahmood SN, Shorr AF (2021) Issues in antibiotic therapy for hospital-acquired and ventilator-associated pneumonia: emerging concepts to improve outcomes. Expert opinion on pharmacotherapy pp. 1\u20137","DOI":"10.1080\/14656566.2021.1908997"},{"issue":"3","key":"3291_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc12705","volume":"17","author":"M Carlier","year":"2013","unstructured":"Carlier M et al (2013) Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used? Crit Care 17(3):1\u20139","journal-title":"Crit Care"},{"issue":"5","key":"3291_CR10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/jac\/dkx526","volume":"73","author":"IK Minichmayr","year":"2018","unstructured":"Minichmayr IK et al (2018) Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. J Antimicrob Chemother 73(5):1330\u20131339","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3291_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jiac.2018.07.007","volume":"24","author":"T Tamatsukuri","year":"2018","unstructured":"Tamatsukuri T et al (2018) The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose. J Infect Chemother 24(10):834\u2013840","journal-title":"J Infect Chemother"},{"issue":"4","key":"3291_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijantimicag.2012.05.010","volume":"40","author":"U Tr\u00f6ger","year":"2012","unstructured":"Tr\u00f6ger U et al (2012) Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents 40(4):370\u2013372","journal-title":"Int J Antimicrob Agents"},{"key":"3291_CR13","doi-asserted-by":"crossref","unstructured":"Pugin J et al (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic blind bronchoalveolar lavage fluid. American Review of Respiratory Disease\u00a0143(5_pt_1):1121\u20131129","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1121"},{"issue":"1","key":"3291_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc12544","volume":"17","author":"AA Udy","year":"2013","unstructured":"Udy AA et al (2013) Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 17(1):1\u20139","journal-title":"Crit Care"},{"issue":"4","key":"3291_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/TA.0000000000001387","volume":"82","author":"JF Barletta","year":"2017","unstructured":"Barletta JF et al (2017) Identifying augmented renal clearance in trauma patients: validation of the augmented renal clearance in trauma intensive care scoring system. J Trauma Acute Care Surg 82(4):665\u2013671","journal-title":"J Trauma Acute Care Surg"},{"issue":"9","key":"3291_CR16","first-page":"e00859","volume":"62","author":"R D'Cunha","year":"2018","unstructured":"D\u2019Cunha R et al (2018) Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 1: assay development and validation. Antimicrob Agents Chemother 62(9):e00859-e918","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3291_CR17","first-page":"99","volume":"2","author":"F Ibrahim","year":"2020","unstructured":"Ibrahim F et al (2020) Analytical methods for the determination of certain antibiotics used in critically ill patients. Pharm Res 2(1):99\u2013117","journal-title":"Pharm Res"},{"issue":"23","key":"3291_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clinmicnews.2019.11.002","volume":"41","author":"TC Abbey","year":"2019","unstructured":"Abbey TC, Deak E (2019) What\u2019s New from the CLSI Subcommittee on Antimicrobial Susceptibility Testing M100. Clin Microbiol Newsl 41(23):203\u2013209","journal-title":"Clin Microbiol Newsl"},{"issue":"5","key":"3291_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","volume":"49","author":"AA Udy","year":"2017","unstructured":"Udy AA et al (2017) Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents 49(5):624\u2013630","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"3291_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA et al (2014) DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58(8):1072\u20131083","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3291_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jac\/dkv288","volume":"71","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH et al (2016) Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother 71(1):196\u2013207","journal-title":"J Antimicrob Chemother"},{"key":"3291_CR22","doi-asserted-by":"crossref","unstructured":"Yu Z et al (2018) Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PloS One\u00a013(7):e0201667","DOI":"10.1371\/journal.pone.0201667"},{"issue":"10","key":"3291_CR23","first-page":"612","volume":"22","author":"J Luo","year":"2019","unstructured":"Luo J et al (2019) Prolonged versus Intermittent Infusion of Antibiotics in Acute and Severe Infections: A Meta-analysis. Arch Iran Med 22(10):612\u2013626","journal-title":"Arch Iran Med"},{"key":"3291_CR24","doi-asserted-by":"crossref","unstructured":"Drusano G (2007) Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45(Supplement_1):S89-S95","DOI":"10.1086\/518137"},{"issue":"4","key":"3291_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1128\/AAC.01330-10","volume":"55","author":"T Lodise","year":"2011","unstructured":"Lodise T et al (2011) Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 55(4):1606\u20131610","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3291_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","volume":"50","author":"KA Rodvold","year":"2011","unstructured":"Rodvold KA, George JM, Yoo L (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid. Clin Pharmacokinet 50(10):637\u2013664","journal-title":"Clin Pharmacokinet"},{"key":"3291_CR27","doi-asserted-by":"crossref","unstructured":"Craig WA (1997)\u00a0The pharmacology of meropenem, a new carbapenem antibiotic.Clin Infect Dis 24(Supplement_2):S266-S275","DOI":"10.1093\/clinids\/24.Supplement_2.S266"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03291-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:08:24Z","timestamp":1649750904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03291-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3291"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03291-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics approval was provided according to local protocols with the ethics committee code of IR.SBMU.PHARMACY.REC.1398.095. The trial was registered at the Iranian Registry of Clinical Trials with the registration number of IRCT20130917014693N12.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}